Total Payments
$195,735
2024 Payments
$7,173
Companies
24
Transactions
220
Medicare Patients
1,063
Medicare Billing
$174,395
Payment Breakdown by Category
Other$99,920 (51.0%)
Consulting$58,907 (30.1%)
Education$17,990 (9.2%)
Travel$12,509 (6.4%)
Food & Beverage$5,086 (2.6%)
Research$1,324 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $94,460 | 39 | 48.3% |
| Consulting Fee | $58,907 | 30 | 30.1% |
| Education | $17,990 | 5 | 9.2% |
| Travel and Lodging | $12,509 | 40 | 6.4% |
| Honoraria | $5,460 | 1 | 2.8% |
| Food and Beverage | $5,086 | 98 | 2.6% |
| Unspecified | $1,324 | 7 | 0.7% |
Payments by Type
General
$194,411
213 transactions
Research
$1,324
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62,269 | 48 | $0 (2024) |
| Seagen Inc. | $36,637 | 22 | $0 (2023) |
| Genentech USA, Inc. | $32,085 | 34 | $0 (2018) |
| Merck Sharp & Dohme LLC | $28,594 | 37 | $0 (2024) |
| Seattle Genetics, Inc. | $23,232 | 29 | $0 (2019) |
| Eisai Inc. | $6,343 | 8 | $0 (2023) |
| Astellas Pharma US Inc | $3,852 | 9 | $0 (2022) |
| PFIZER INC. | $1,088 | 2 | $0 (2024) |
| Genentech, Inc. | $707.40 | 4 | $0 (2019) |
| Astellas Pharma Global Development | $170.83 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,173 | 9 | Merck Sharp & Dohme LLC ($4,295) |
| 2023 | $40,290 | 14 | Seagen Inc. ($21,548) |
| 2022 | $16,876 | 20 | Seagen Inc. ($8,733) |
| 2021 | $18,963 | 10 | Merck Sharp & Dohme Corporation ($11,080) |
| 2020 | $12,837 | 18 | Merck Sharp & Dohme Corporation ($3,000) |
| 2019 | $21,827 | 57 | Seattle Genetics, Inc. ($17,581) |
| 2018 | $29,079 | 39 | E.R. Squibb & Sons, L.L.C. ($21,017) |
| 2017 | $48,691 | 53 | Genentech USA, Inc. ($24,461) |
All Payment Transactions
220 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $305.00 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $77.86 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 07/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $1,791.00 | General |
| Category: Oncology | ||||||
| 03/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $711.67 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $147.59 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $29.92 | General |
| 11/20/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,035.00 | General |
| 11/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $47.72 | General |
| 06/16/2023 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $113.36 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $59.64 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $59.30 | General |
| Category: Oncology | ||||||
| 04/28/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $1,790.67 | General |
| Category: Oncology | ||||||
| 03/10/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $14,228.00 | General |
| Category: Oncology | ||||||
| 01/25/2023 | Seagen Inc. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $17,000.00 | General |
| Category: Oncology | ||||||
| 01/25/2023 | Seagen Inc. | PADCEV (Biological) | Travel and Lodging | In-kind items and services | $861.23 | General |
| Category: Oncology | ||||||
| 01/25/2023 | Seagen Inc. | PADCEV (Biological) | Travel and Lodging | In-kind items and services | $291.84 | General |
| Category: Oncology | ||||||
| 01/25/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $37.95 | General |
| Category: Oncology | ||||||
| 12/31/2022 | Astellas Pharma US Inc | PADCEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $730.00 | General |
| Category: Oncology | ||||||
| 12/05/2022 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ASP1941 Phase II Clinical Study A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients with Type 2 Diabetes Mellitus | Astellas Pharma Global Development | $170.83 | 2 |
| A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer | Seattle Genetics, Inc. | $99.00 | 1 |
| A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor CPI therapy | Seattle Genetics, Inc. | $92.03 | 2 |
| BETi/PLX2853 | Plexxikon Inc. | $22.46 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 333 | 524 | $169,243 | $49,993 |
| 2022 | 6 | 340 | 579 | $198,082 | $59,499 |
| 2021 | 3 | 244 | 406 | $150,401 | $47,460 |
| 2020 | 4 | 146 | 205 | $60,941 | $17,442 |
Total Patients
1,063
Total Services
1,714
Medicare Billing
$174,395
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 117 | 252 | $86,688 | $26,558 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 63 | 63 | $30,870 | $7,959 | 25.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 79 | $20,145 | $5,470 | 27.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 37 | $9,250 | $3,347 | 36.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $7,776 | $2,110 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 35 | $6,090 | $2,104 | 34.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 25 | 30 | $5,160 | $1,452 | 28.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 12 | 12 | $3,264 | $994.22 | 30.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 152 | 324 | $111,456 | $34,369 | 30.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 87 | 87 | $42,630 | $11,981 | 28.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 73 | $18,250 | $5,820 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 56 | $14,280 | $3,638 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $7,290 | $2,385 | 32.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 24 | $4,176 | $1,306 | 31.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 129 | 290 | $99,906 | $32,901 | 32.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 89 | 89 | $43,610 | $12,502 | 28.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 26 | 27 | $6,885 | $2,058 | 29.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 81 | $26,804 | $7,222 | 26.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 41 | 41 | $19,958 | $5,284 | 26.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 13 | 22 | $5,236 | $1,949 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 17 | 24 | $3,792 | $1,299 | 34.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 20 | $3,451 | $1,075 | 31.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 17 | $1,700 | $612.30 | 36.0% |
About Dr. Christopher Hoimes, DO
Dr. Christopher Hoimes, DO is a Hematology & Oncology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780634188.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Hoimes, DO has received a total of $195,735 in payments from pharmaceutical and medical device companies, with $7,173 received in 2024. These payments were reported across 220 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($94,460).
As a Medicare-enrolled provider, Hoimes has provided services to 1,063 Medicare beneficiaries, totaling 1,714 services with total Medicare billing of $174,395. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine, Hospitalist
- Location Cleveland, OH
- Active Since 05/10/2006
- Last Updated 07/18/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1780634188
Products in Payments
- OPDIVO (Biological) $57,326
- PADCEV (Biological) $35,249
- TECENTRIQ (Biological) $32,003
- Lenvima (Drug) $6,265
- ASG22 (Biological) $5,460
- KEYTRUDA (Biological) $5,051
- PADCEV (Drug) $3,961
- EMPLICITI (Biological) $3,567
- Non-Covered Product (Drug) $674.40
- INLYTA (Drug) $147.59
- JEVTANA (Drug) $125.04
- PROVENGE (Drug) $121.13
- Cabometyx (Drug) $92.66
- XTANDI (Drug) $88.62
- ALIMTA (Drug) $44.22
- Bavencio (Biological) $40.06
- DARZALEX (Biological) $18.88
- SOMATULINE DEPOT (Drug) $16.29
- Abraxane (Drug) $15.44
- IMBRUVICA (Drug) $15.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cleveland
Hillard Lazarus, Md, MD
Hematology & Oncology — Payments: $2.5M
Hematology & Oncology $2.5M
Jorge Garcia, Md, MD
Hematology & Oncology — Payments: $765,093
Hematology & Oncology $765,093
Ronald Bukowski, Md, MD
Hematology & Oncology — Payments: $744,876
Hematology & Oncology $744,876
Balazs Halmos, Md, MD
Hematology & Oncology — Payments: $548,525
Hematology & Oncology $548,525
Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $481,414
Hematology & Oncology $481,414
Bachar Dergham, Md, MD
Hematology & Oncology — Payments: $456,653
Hematology & Oncology $456,653